Your browser doesn't support javascript.
loading
Identification of anti-virulence compounds that disrupt quorum-sensing regulated acute and persistent pathogenicity.
Starkey, Melissa; Lepine, Francois; Maura, Damien; Bandyopadhaya, Arunava; Lesic, Biljana; He, Jianxin; Kitao, Tomoe; Righi, Valeria; Milot, Sylvain; Tzika, Aria; Rahme, Laurence.
Afiliação
  • Starkey M; Department of Surgery, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, United States of America; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America; Shriners Hospitals for Children Boston, Boston, Ma
  • Lepine F; INRS-Institut Armand Frappier, Laval, Québec, Canada.
  • Maura D; Department of Surgery, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, United States of America; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America; Shriners Hospitals for Children Boston, Boston, Ma
  • Bandyopadhaya A; Department of Surgery, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, United States of America; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America; Shriners Hospitals for Children Boston, Boston, Ma
  • Lesic B; Department of Surgery, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, United States of America; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America; Shriners Hospitals for Children Boston, Boston, Ma
  • He J; Department of Surgery, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, United States of America; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America; Shriners Hospitals for Children Boston, Boston, Ma
  • Kitao T; Department of Surgery, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, United States of America; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America; Shriners Hospitals for Children Boston, Boston, Ma
  • Righi V; NMR Surgical Laboratory, Department of Surgery, Massachusetts General and Shriners Hospitals, Harvard Medical School, Boston, Massachusetts, United States of America; Athinoula A. Martinos Center of Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, U
  • Milot S; INRS-Institut Armand Frappier, Laval, Québec, Canada.
  • Tzika A; NMR Surgical Laboratory, Department of Surgery, Massachusetts General and Shriners Hospitals, Harvard Medical School, Boston, Massachusetts, United States of America; Athinoula A. Martinos Center of Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, U
  • Rahme L; Department of Surgery, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, United States of America; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America; Shriners Hospitals for Children Boston, Boston, Ma
PLoS Pathog ; 10(8): e1004321, 2014 Aug.
Article em En | MEDLINE | ID: mdl-25144274
ABSTRACT
Etiological agents of acute, persistent, or relapsing clinical infections are often refractory to antibiotics due to multidrug resistance and/or antibiotic tolerance. Pseudomonas aeruginosa is an opportunistic Gram-negative bacterial pathogen that causes recalcitrant and severe acute chronic and persistent human infections. Here, we target the MvfR-regulated P. aeruginosa quorum sensing (QS) virulence pathway to isolate robust molecules that specifically inhibit infection without affecting bacterial growth or viability to mitigate selective resistance. Using a whole-cell high-throughput screen (HTS) and structure-activity relationship (SAR) analysis, we identify compounds that block the synthesis of both pro-persistence and pro-acute MvfR-dependent signaling molecules. These compounds, which share a benzamide-benzimidazole backbone and are unrelated to previous MvfR-regulon inhibitors, bind the global virulence QS transcriptional regulator, MvfR (PqsR); inhibit the MvfR regulon in multi-drug resistant isolates; are active against P. aeruginosa acute and persistent murine infections; and do not perturb bacterial growth. In addition, they are the first compounds identified to reduce the formation of antibiotic-tolerant persister cells. As such, these molecules provide for the development of next-generation clinical therapeutics to more effectively treat refractory and deleterious bacterial-human infections.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pseudomonas aeruginosa / Infecções por Pseudomonas / Farmacorresistência Bacteriana / Percepção de Quorum / Descoberta de Drogas / Antibacterianos Tipo de estudo: Diagnostic_studies Limite: Animals Idioma: En Revista: PLoS Pathog Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Marrocos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pseudomonas aeruginosa / Infecções por Pseudomonas / Farmacorresistência Bacteriana / Percepção de Quorum / Descoberta de Drogas / Antibacterianos Tipo de estudo: Diagnostic_studies Limite: Animals Idioma: En Revista: PLoS Pathog Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Marrocos